Who is bridge Biotherapeutics?

Bridge Biotherapeutics Inc., based in the Republic of Korea, US, and China, is a publicly-traded, clinical-stage biotech company founded in 2015. Bridge Biotherapeutics is engaged in the discovery and development of novel therapeutics, focusing on therapeutic areas with high unmet needs including ulcerative colitis, fibrotic diseases, and cancers.

Where can I find information about bridge Biotherapeutics' Phase 2 clinical study?

Bridge plans to initiate the 24-week Phase 2 clinical study later this year. The multi-country study will include approximately 50 clinical sites in North America, Asia, and Europe. Further information is available at www.clinicaltrials.gov/show/NCT05483907. About Bridge Biotherapeutics, Inc.

Why did bridge Biotherapeutics approve bbt-877?

"We're excited to continue the clinical development of BBT-877 in order to address unmet medical needs of IPF," said James Lee, founder and CEO of Bridge Biotherapeutics. "With this approval, the company remains focused on developing novel treatment options for multiple fibrotic diseases, including IPF."